Biocytogen Pharmaceuticals Beijing Co Ltd
HKEX:2315
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (6), the stock would be worth HK$37.78 (27% downside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 8.3 | HK$51.7 |
0%
|
| 3-Year Average | 6 | HK$37.78 |
-27%
|
| 5-Year Average | 7.2 | HK$44.78 |
-13%
|
| Industry Average | 4.2 | HK$26.01 |
-50%
|
| Country Average | 2.4 | HK$15.3 |
-70%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
B
|
Biocytogen Pharmaceuticals Beijing Co Ltd
HKEX:2315
|
20.6B HKD | 8.3 | 103.9 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -164 720.7 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
360.5B USD | -110.2 | 86.1 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
182.2B USD | 21 | 23.6 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
159.9B USD | 7 | 18.8 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -5 465.3 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
107.5B USD | 5.8 | 27.2 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
72.5B USD | 2.3 | 16.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
40.6B EUR | 6.5 | 36.7 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 18.2 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
60.6B AUD | 2.2 | 29.7 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.5 |
| Median | 2.4 |
| 70th Percentile | 3.9 |
| Max | 1 172 445.9 |
Other Multiples
Biocytogen Pharmaceuticals Beijing Co Ltd
Glance View
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. manufactures biological products and provides related biological services. The company is headquartered in Beijing, Beijing. The company went IPO on 2022-09-01. The firm operates two business segments. The Drug Development Business segment is mainly engaged in the research and development of oncology and autoimmune disease treatments, as well as antibody development. The Preclinical Research Service segment is mainly engaged in gene editing, preclinical pharmacological efficacy evaluation and model animal sales.
